CARDINAL HEALTH INC Q1 FY2025 earnings call

Management Statement and Operational Highlights

• Pharma and Specialty: Strong pharmaceutical demand across categories, successful customer transition execution, and positive performance in Brand, Specialty, Consumer Health, and Generics. Started onboarding new Pharma customers contributing to incremental revenue.
• GMPD: Continuing to execute the GMPD Improvement Plan, making operational progress, and taking actions to enhance supply chain resiliency despite challenges from health and welfare costs and manufacturing expenses.
• Other: Nuclear, at-Home, and OptiFreight showing positive growth. Announced acquisition of Integrated Oncology Network for $1.1 billion to strengthen specialty offerings. Biopharma Solutions launched Advanced Therapy Connect provider ordering solution.
• Operational Efficiencies: Pharma segment achieved multi-year highs in productivity and service levels. GMPD team making progress on improvement plan initiatives. Other businesses investing in growth and capabilities, like OptiFreight in tech forward platforms.

Segment Performance

• Pharma and Specialty Solutions: Q1 revenue decreased 5% to $48 billion due to customer transition; excluding this, revenue increased 16%, driven by brand and specialty pharmaceutical sales growth (including 5 percentage points from GLP-1 sales). Segment profit increased 16% to $530 million, driven by strong performance in Brand, Specialty, Consumer Health, and Generics programs. COVID-19 vaccine distribution for fall season was also supported.
• GMPD: Revenue increased 3% to $3.1 billion in Q1, but segment profit decreased to $8 million due to unanticipated health and welfare costs and increased manufacturing costs. The team continues to work on the GMPD Improvement Plan.
• Other businesses: Nuclear, at-Home, and OptiFreight saw revenue increase 13% to $1.2 billion in Q1. Segment profit grew 8%, with OptiFreight having a strong quarter due to growing demand for healthcare logistics, technology, and services.

Guidance

• Enterprise: Raised EPS guidance to $7.75 - $7.90 and adjusted free cash flow guidance to $1 billion - $1.5 billion for fiscal '25.
• Pharma and Specialty Solutions: Improved revenue outlook to a decline of 2% - 4% (midpoint 18% - 20% growth ex customer transition), and raised segment profit guidance to 4% - 6% growth for the year. Q2 expected to be slightly down due to COVID-19 headwind, with growth resuming in Q3 and Q4.
• GMPD: Adjusted segment profit outlook to $140 million - $175 million for fiscal '25, with back-half weighted profit and sequential improvements. Q2 expected to be impacted by higher manufacturing costs and carryover from health and welfare plan utilization in Q1.
• Other: Reiterated 10% - 12% revenue growth and approximately 10% segment profit growth for the year, but Nuclear business expected to moderate in Q2 due to Moly-99 raw material shortage, with volumes expected to return in subsequent quarters.

Risks

• GMPD: Unanticipated health and welfare costs, increased manufacturing costs, and potential impacts from macro challenges like tariffs.
• Nuclear: Industry-wide raw material shortage of Moly-99 impacting volume and profitability in Q2.
• General: Market uncertainties, customer transition impacts, and potential fluctuations in pharmaceutical and healthcare industry dynamics that could affect financial performance.

Q: How to think about the vaccine contribution to margin and the Specialty side?

A: Jason Hollar stated strong broad-based volume across Pharma was the primary driver, with COVID vaccine volume a slight tailwind in Q1 but not a significant driver of year-over-year results. Specialty growth was a component of underlying growth but not the main driver.

Q: Bridge the gap on the 300-basis-point uptick in Pharma guidance for the year?

A: Aaron Alt mentioned strong broad-based demand, successful execution of customer transition, simplification progress, consistent market dynamics in Generics, and contributions from Brand and Specialty Products. COVID-19 guidance remains a modest headwind for the year with offsetting factors carrying forward.

Q: Commentary on GMPD profit progression and manufacturing costs?

A: Aaron Alt said GMPD was on track with improvement plan despite Q1 health and wellness costs, which had a $45 million enterprise impact. Manufacturing costs had a similar dollar impact to health and wellness in Q1. Jason Hollar emphasized managing on gross margin dollars and focus on balance between SG&A and gross margin.

Q: Thoughts on GLP-1 economics and STELARA pricing impact?

A: Jason Hollar stated GLP-1 economics didn't drive the guidance change and was a component of broad strength. For STELARA, the model of fixed fee for service continues as they provide same service and expect same financial compensation regardless of price changes.

Q: Nuclear supply shortage timeline and simplification efforts?

A: Jason Hollar said Moly-99 reactor downtime expected to be resolved within the quarter, with volumes returning in subsequent quarters. Simplification is an ongoing journey across the enterprise, with opportunities in GMPD and other businesses, and investments in automation and process improvements to drive efficiency.